ReviewDialogues in clinical neuroscience2011
Depressogenic effects of medications: a review.
Review in Dialogues in clinical neuroscience, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Women Undergoing Hormonal Treatments for Infertility: A Systematic Review on Psychopathology and Newly Diagnosed Mood and Psychotic Disorders.Frontiers in psychiatry · 2020Pooled it
- Association of Microvascular Dysfunction With Late-Life Depression: A Systematic Review and Meta-analysis.JAMA psychiatry · 2017Pooled it
- Patient perspectives on group problem management plus for adults with major depressive disorder in rural Malawi.Global health action · 2025Trial
- Association Between Depressive Symptoms and Self-Reported Ongoing Medication Use Among Pharmacy Students: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2026Article
- Clinical practice guideline for assessment and management of depression in India.Indian journal of psychiatry · 2026Article
- Mechanistic intersections between migraine and major depressive disorder.The journal of headache and pain · 2025Review
- Development and Validation of a Nomogram to Predict Depression Risk in Patients with Cardiovascular Disease.Healthcare (Basel, Switzerland) · 2025Article
- Development and Validation of Polypharmacy-Related Psychological Distress Scale (PPDS): A Preliminary Study.Behavioral sciences (Basel, Switzerland) · 2025Article
- Risk factor analysis and establishment of a predictive model for epilepsy comorbid with depression.PloS one · 2025Article
- Assessment of the Correlation Between Obesity and Depression Among Adults in Saudi Arabia.Cureus · 2024Article
- Migraine Comorbidities.Life (Basel, Switzerland) · 2024Review
- Article
- Efficacy and Safety of Clonidine in the Treatment of Acute Mania in Bipolar Disorder: A Systematic Review.Brain sciences · 2023Review
- Impact of the COVID-19 pandemic on older adults living in long-term care centers in Thailand, and risk factors for post-traumatic stress, depression, and anxiety.Journal of affective disorders · 2021Article
- Psychological Backgrounds of Medically Compromised Patients and Its Implication in Dentistry: A Narrative Review.International journal of environmental research and public health · 2021Review
- The relationship between antihypertensive medications and mood disorders: analysis of linked healthcare data for 1.8 million patients.Psychological medicine · 2021Article
- Serotonergic Neurotransmission System Modulator, Vortioxetine, and Dopaminergic DMolecules (Basel, Switzerland) · 2021Article
- Isotretinoin in Acne Vulgaris Complicated by Underlying Major Depression: A Case Report and Review of Literature.Case reports in psychiatry · 2021Article
- Study protocol: a prospective cohort on non-communicable diseases among primary healthcare users living in Kosovo (KOSCO).BMJ open · 2020Article
- Differential gene expression profile analysis in corticosterone-treated PC12 cells.International journal of clinical and experimental pathology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The literature is filled with reports that link medications with the onset or progression of depression. Because depression is so common in patients with medical illness, assessing whether a medication has in fact caused depression, or whether the relationship is coincidental, can be challenging. In this article, we review the literature on the association between medications and depression. For most agents, there are case reports or small studies linking the medication with the onset of depression, but more rigorous prospective studies are either lacking or found no association between the agent and depression. However, several medications, (eg, barbiturates, vigabatrin, topiramate, flunarizine, corticosteroids, mefloquine, efavirenz, and interferon-alpha) do appear to cause depression in some patients and should be used with caution in patients at risk for depression.
Indexed as
Identifiers
21485751PMC3181967W1512048841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.